首页 | 本学科首页   官方微博 | 高级检索  
     


Modified pharmacokinetic modulating chemotherapy using 5-fluorouracil,UFT, and taxotere (docetaxel) for advanced gastric cancer
Authors:Kouji?Tanaka,Naomi?Konishi,Yukinari?Ohmori,Minako?Kobayashi,Yasuhiko?Mohri,Hitoshi?Tonouchi,Masato?Kusunoki  mailto:kusunoki@clin.medic.mie-u.ac.jp"   title="  kusunoki@clin.medic.mie-u.ac.jp"   itemprop="  email"   data-track="  click"   data-track-action="  Email author"   data-track-label="  "  >Email author
Affiliation:(1) The Second Department of Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan;(2) Department of Innovative Surgery, Mie University School of Medicine, Mie, Japan
Abstract:
The efficacy of neoadjuvant chemotherapy for advanced gastric carcinoma is controversial. Moreover, a standard regimen for such chemotherapy has not been clearly established. Pharmacokinetic modulating chemotherapy (PMC), a combination of infused 5-fluorouracil and oral uracil-tegafur, has been proven to be highly effective for the treatment of colorectal carcinoma. We report two patients with advanced gastric carcinoma successfully treated with PMC and infused taxotere (TXT; docetaxel). Preoperative treatment with PMC and TXT significantly decreased the depth of wall penetration of the tumor in one patient and reduced the size of the tumor in the other patient. In both patients, there were significant chemotherapeutic effects on the primary tumor and on regional lymph nodes pathologically. Preoperative PMC plus TXT produced primary tumor downstaging, leading to improved resectability. The responsiveness of metastatic cancer cells in the regional lymph nodes suggested the possibility of nodal downstaging by this regimen.
Keywords:Advanced gastric cancer  Neoadjuvant chemotherapy  5-Fluorouracil  UFT (uracil-tegafur)  Taxotere (docetaxel)
本文献已被 PubMed SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号